Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Compare

589 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RYTM Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Rhythm

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RYTM Stock 12 Month Forecast

Average Price Target

$139.54

▲(53.09% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is $139.54 with a high forecast of $176.00 and a low forecast of $110.00. The average price target represents a 53.09% change from the last price of $91.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"49":"$49","81":"$81","113":"$113","145":"$145","177":"$177"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$176.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":139.54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$139.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[49,81,113,145,177],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.94,101.17538461538462,107.41076923076923,113.64615384615385,119.88153846153847,126.11692307692309,132.3523076923077,138.5876923076923,144.82307692307694,151.05846153846153,157.29384615384618,163.52923076923076,169.76461538461538,{"y":176,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.94,98.37076923076923,101.80153846153846,105.23230769230769,108.66307692307691,112.09384615384614,115.52461538461537,118.95538461538462,122.38615384615383,125.81692307692308,129.2476923076923,132.67846153846153,136.10923076923075,{"y":139.54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.94,96.09846153846154,97.25692307692307,98.41538461538461,99.57384615384615,100.73230769230769,101.89076923076922,103.04923076923077,104.20769230769231,105.36615384615385,106.52461538461539,107.68307692307692,108.84153846153846,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.94,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$176.00

Average Price Target$139.54

Lowest Price Target$110.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Derek Archila

Wells Fargo

$136→$143

Buy

56.88%

Upside

Assigned

03/12/26

Rhythm Pharmaceuticals price target raised to $143 from $136 at Wells FargoRhythm Pharmaceuticals price target raised to $143 from $136 at Wells Fargo

Dennis Ding

Jefferies

$125

Buy

37.14%

Upside

Reiterated

03/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Altimmune (NASDAQ: ALT), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Cormedix (NASDAQ: CRMD)

Michael Ulz

Morgan Stanley

$150

Buy

64.56%

Upside

Reiterated

03/05/26

Analysts' Top Healthcare Picks: Veeva Systems (VEEV), Omnicell (OMCL)

Whitney Ijem

Canaccord Genuity

$140

Buy

53.59%

Upside

Reiterated

03/03/26

Rhythm Pharmaceuticals price target lowered to $140 from $141 at CanaccordRhythm Pharmaceuticals price target lowered to $140 from $141 at Canaccord

Ram Selvaraju

H.C. Wainwright

$125→$110

Buy

20.68%

Upside

Reiterated

03/02/26

Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. WainwrightRhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright

Paul Matteis

Stifel Nicolaus

$131

Buy

43.72%

Upside

Reiterated

03/02/26

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)

Jonathan Wolleben

Citizens JMP

$167→$176

Buy

93.09%

Upside

Reiterated

02/27/26

Rhythm Pharmaceuticals price target raised to $176 from $167 at CitizensRhythm Pharmaceuticals price target raised to $176 from $167 at Citizens

Joseph Stringer

Needham

$148→$139

Buy

52.50%

Upside

Reiterated

02/26/26

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Teleflex (TFX)

Seamus Fernandez

Guggenheim

$140→$143

Buy

56.88%

Upside

Reiterated

02/26/26

Rhythm Pharmaceuticals price target raised to $143 from $140 at GuggenheimRhythm Pharmaceuticals price target raised to $143 from $140 at Guggenheim

Phil Nadeau

TD Cowen

$130

Buy

42.62%

Upside

Reiterated

02/26/26

Rhythm Pharmaceuticals: Imcivree Momentum and Bivamelanotide Pipeline Catalysts Underpin Buy Rating and $130 Target

Lisa Walter

RBC Capital

$145→$140

Buy

53.59%

Upside

Reiterated

02/26/26

Rhythm Pharmaceuticals (RYTM) Receives a Buy from RBC Capital

Tazeen Ahmad

Bank of America Securities

$145

Buy

59.08%

Upside

Reiterated

01/30/26

Bank of America Securities Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

Faisal Khurshid

Leerink Partners

$135→$142

Buy

55.79%

Upside

Reiterated

12/15/25

Leerink Partners Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)

Corinne Johnson

Goldman Sachs

$141→$157

Buy

72.24%

Upside

Reiterated

12/12/25

Goldman Sachs Remains a Buy on Rhythm Pharmaceuticals (RYTM)

Samantha Semenkow

Citi

$136

Buy

49.20%

Upside

Initiated

11/25/25

Rhythm Pharmaceuticals initiated with a Buy at CitiRhythm Pharmaceuticals initiated with a Buy at Citi

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Derek Archila

Wells Fargo

$136→$143

Buy

56.88%

Upside

Assigned

03/12/26

Rhythm Pharmaceuticals price target raised to $143 from $136 at Wells FargoRhythm Pharmaceuticals price target raised to $143 from $136 at Wells Fargo

Dennis Ding

Jefferies

$125

Buy

37.14%

Upside

Reiterated

03/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Altimmune (NASDAQ: ALT), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Cormedix (NASDAQ: CRMD)

Michael Ulz

Morgan Stanley

$150

Buy

64.56%

Upside

Reiterated

03/05/26

Analysts' Top Healthcare Picks: Veeva Systems (VEEV), Omnicell (OMCL)

Whitney Ijem

Canaccord Genuity

$140

Buy

53.59%

Upside

Reiterated

03/03/26

Rhythm Pharmaceuticals price target lowered to $140 from $141 at CanaccordRhythm Pharmaceuticals price target lowered to $140 from $141 at Canaccord

Ram Selvaraju

H.C. Wainwright

$125→$110

Buy

20.68%

Upside

Reiterated

03/02/26

Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. WainwrightRhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright

Paul Matteis

Stifel Nicolaus

$131

Buy

43.72%

Upside

Reiterated

03/02/26

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)

Jonathan Wolleben

Citizens JMP

$167→$176

Buy

93.09%

Upside

Reiterated

02/27/26

Rhythm Pharmaceuticals price target raised to $176 from $167 at CitizensRhythm Pharmaceuticals price target raised to $176 from $167 at Citizens

Joseph Stringer

Needham

$148→$139

Buy

52.50%

Upside

Reiterated

02/26/26

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Teleflex (TFX)

Seamus Fernandez

Guggenheim

$140→$143

Buy

56.88%

Upside

Reiterated

02/26/26

Rhythm Pharmaceuticals price target raised to $143 from $140 at GuggenheimRhythm Pharmaceuticals price target raised to $143 from $140 at Guggenheim

Phil Nadeau

TD Cowen

$130

Buy

42.62%

Upside

Reiterated

02/26/26

Rhythm Pharmaceuticals: Imcivree Momentum and Bivamelanotide Pipeline Catalysts Underpin Buy Rating and $130 Target

Lisa Walter

RBC Capital

$145→$140

Buy

53.59%

Upside

Reiterated

02/26/26

Rhythm Pharmaceuticals (RYTM) Receives a Buy from RBC Capital

Tazeen Ahmad

Bank of America Securities

$145

Buy

59.08%

Upside

Reiterated

01/30/26

Bank of America Securities Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

Faisal Khurshid

Leerink Partners

$135→$142

Buy

55.79%

Upside

Reiterated

12/15/25

Leerink Partners Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)

Corinne Johnson

Goldman Sachs

$141→$157

Buy

72.24%

Upside

Reiterated

12/12/25

Goldman Sachs Remains a Buy on Rhythm Pharmaceuticals (RYTM)

Samantha Semenkow

Citi

$136

Buy

49.20%

Upside

Initiated

11/25/25

Rhythm Pharmaceuticals initiated with a Buy at CitiRhythm Pharmaceuticals initiated with a Buy at Citi

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rhythm Pharmaceuticals

3 Months

xxx

Success Rate

17/21 ratings generated profit

Average Return

+17.42%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +17.42% per trade.

1 Year

Whitney IjemCanaccord Genuity

Success Rate

19/21 ratings generated profit

Average Return

+64.47%

reiterated a buy rating 11 days ago

Copying Whitney Ijem's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +64.47% per trade.

2 Years

xxx

Success Rate

16/19 ratings generated profit

Average Return

+137.75%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.21% of your transactions generating a profit, with an average return of +137.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RYTM Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RYTM has received 22 Buy Ratings, 22 Hold Ratings, and 0 Sell Ratings. RYTM average Analyst price target in the past 3 months is 139.54.

Each month's total comprises the sum of three months' worth of ratings.

RYTM Financial Forecast

RYTM Earnings Forecast

Next quarter’s earnings estimate for RYTM is -$0.82 with a range of -$0.98 to -$0.52. The previous quarter’s EPS was -$0.73. RYTM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.

RYTM Sales Forecast

Next quarter’s sales forecast for RYTM is $56.25M with a range of $51.00M to $61.00M. The previous quarter’s sales results were $57.25M. RYTM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.

RYTM Stock Forecast FAQ

What is RYTM’s average 12-month price target, according to analysts?

Based on analyst ratings, Rhythm Pharmaceuticals Inc’s 12-month average price target is 139.54.

What is RYTM’s upside potential, based on the analysts’ average price target?

Rhythm Pharmaceuticals Inc has 53.09% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RYTM a Buy, Sell or Hold?

Rhythm Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Rhythm Pharmaceuticals Inc’s price target?

The average price target for Rhythm Pharmaceuticals Inc is 139.54. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $176.00 ,the lowest forecast is $110.00. The average price target represents 53.09% Increase from the current price of $91.15.

What do analysts say about Rhythm Pharmaceuticals Inc?

Rhythm Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of RYTM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

RYTM Analyst Ratings

RYTM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Rhythm Pharmaceuticals

RYTM Analyst Recommendation Trends

RYTM Financial Forecast

RYTM Earnings Forecast

RYTM Sales Forecast

RYTM Stock Forecast FAQ

Detailed List of Analyst Forecasts